Quetiapine Excretion Into Human Breast Milk

J Clin Psychopharmacol. 2018 Aug;38(4):362-364. doi: 10.1097/JCP.0000000000000905.

Abstract

Background: Risk assessment of the use of quetiapine during breastfeeding is challenging owing to a paucity of data.

Methods: A pharmacokinetic study was conducted in lactating women who were taking quetiapine. The primary endpoint was to determine quetiapine concentration profiles in milk and estimated infant exposure levels. Multiple milk and a single blood quetiapine concentrations were determined using a highly sensitive liquid chromatography with tandem mass spectroscopy method.

Results: Nine subjects receiving fast-release quetiapine (mean dose, 41 mg/d) were analyzed at steady state. The mean milk/plasma drug concentration ratio at 2-hour postdose was 0.47 (SD, 0.50; range, 0.13-1.67). The mean milk concentration of each patient was 5.7 ng/mL (SD, 4.5; range, 1.4-13.9 ng/mL). The mean infant quetiapine dose via milk per body weight relative to weight-adjusted maternal dose was 0.16 % (SD, 0.08; range, 0.04%-0.35%).

Conclusions: Infant exposure levels to quetiapine via milk are predicted to be very small.

MeSH terms

  • Antipsychotic Agents / analysis
  • Antipsychotic Agents / blood
  • Antipsychotic Agents / pharmacokinetics*
  • Chromatography, High Pressure Liquid
  • Female
  • Humans
  • Milk, Human / chemistry*
  • Quetiapine Fumarate / analysis
  • Quetiapine Fumarate / blood
  • Quetiapine Fumarate / pharmacokinetics*
  • Tandem Mass Spectrometry

Substances

  • Antipsychotic Agents
  • Quetiapine Fumarate